GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
As part of the agreement, Emergent will retain the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene. Emergent continues to operate a streamlined manufacturing network, including facilities in Lansing, Michigan and Winnipeg, Manitoba, Canada capable of serving strategic partners and supporting large-scale projects.
“The sale of Bayview represents a continuation of our efforts to deliver on our multi-year transformation plan and creates a streamlined, customer-focused, leaner, more flexible organization that provides the capabilities to deliver our product demand today and into the future,” said Joe Papa, president and CEO of Emergent. “Now in our turnaround phase, we see significant opportunities for Emergent’s core products and future growth drivers that have the potential to protect and save countless lives.”
In March 2024, Emergent received a favorable inspection outcome, “No Action Indicated” or NAI status classification from the U.S. Food and Drug Administration (FDA) for the …
